medigraphic.com
Instituto Nacional de Salud Pública

2008, Número 2

<< Anterior Siguiente >>

salud publica mex 2008; 50 (2)


Factores pronósticos relacionados con la supervivencia del cáncer de mama

Flores-Luna L, Salazar-Martínez E, Duarte-Torres RM, Torres-Mejía G, Alonso-Ruiz P, Lazcano-Ponce E

Idioma: Español
Referencias bibliográficas: 43
Paginas: 119-125
Archivo PDF: 162.69 Kb.


RESUMEN

Objetivo. Evaluar los factores pronósticos del cáncer de mama en mujeres mexicanas. Material y métodos. Se incluyó a 432 mujeres con cáncer de mama admitidas de 1990 a 1999 en el Hospital General de México para evaluar la supervivencia mediante las técnicas de Kaplan-Meier y los métodos de riesgos proporcionales de Cox. Resultados. La supervivencia global a cinco años fue de 58.9%. La menor supervivencia corresponde a los estadios clínicos IIIB (47.5%), IIIA (44.2%) y IV(15%), la metástasis hematógena fue de 21.4% y el tumor positivo en bordes quirúrgicos de 12.5%. La invasión linfovascular (RR= 1.9; IC95% 1.3-2.8), el estadio clínico IV (RR= 14.8; IC95% 5.5-39.7) y el tumor en bordes quirúrgicos (RR= 2.4; IC95% 1.2-4.8) fueron los principales factores pronósticos. Conclusiones. Estos resultados dan consistencia a los criterios de diagnóstico y tratamiento de las mujeres con cáncer de mama atendidas en México y toman en consideración las condiciones de la tumoración, como extensión de la malformación, etapa clínica y estado de los ganglios linfáticos antes de decidir la conducta terapéutica inicial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancerepidemiology, risk factors, and genetics. BMJ 2000;321(7261):624-628.

  2. López-Ríos O, Lazcano-Ponce EC, Tovar-Guzman V, Hernández-Avila M. Epidemiology of cancer of the breast in Mexico. Consequences of demography transition. Salud Publica Mex 1997;39(4):259-265.

  3. Romieu I, Lazcano-Ponce E, Sanchez-Zamorano LM, Willett W, Hernández-Avila M. Carbohydrates and the risk of breast cancer among Mexican women. Cancer Epidemiol Biomarkers Prev 2004;13(8):1283-1289.

  4. Rivera DJ SL, Villalpando HS, González CT, Hernández PB. Encuesta Nacional de nutrición 1999. Estado nutricional de niños y mujeres en México. Cuernavaca: Instituto Nacional de Salud Pública, 2001.

  5. Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 1994;102(4 suppl 1):S3-S8.

  6. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, et al. Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27(3):219-226.

  7. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992;20(6):479-489.

  8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19(5):403-410.

  9. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991;265(3):391-395.

  10. Dabbs DJ, Silverman JF. Prognostic factors from the fineneedle aspirate: breast carcinoma nuclear grade. Diagn Cytopathol 1994;10(3):203-208.

  11. Masood S. Prognostic factors in breast cancer: use of cytologic preparations. Diagn Cytopathol 1995;13(5):388-395.

  12. Fisher ER, Redmond C, Fisher B, Bass G. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer 1990;65(9 suppl):2121-2128.

  13. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62(12): 2507-2516.

  14. Ciatto S, Bonardi R, Herd-Smith A, Cariaggi P, Confortini M, Bulgaresi P. Prognostic value of breast cancer cytologic grading: a retrospective study of 213 cases. Diagn Cytopathol 1993;9(2):160-163.

  15. Dabbs DJ. Role of nuclear grading of breast carcinomas in fine needle aspiration specimens. Acta Cytol 1993;37(3):361-366.

  16. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63(1): 181-187.

  17. Price JE. The biology of metastatic breast cancer. Cancer 1990;66 (6 suppl):1313-1320.

  18. Lage A, Rodriguez M, Pascual MR, Diaz JW, Fernandez L. Factors associated with prognosis in human breast cancer. I. Predictors for rate of evolution and relapse. Neoplasma 1983;30(4):475-483.

  19. Schaefer G, Rosen PP, Lesser ML, Kinne DW, Beattie EJ, Jr. Breast carcinoma in elderly women: pathology, prognosis, and survival. Pathol Annu 1984;19(Pt 1):195-219.

  20. Young JL Jr, Ries LG, Pollack ES. Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 1984;73(2):341-352.

  21. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80(9):1803-1804.

  22. Kaplan MP. Nonparametric estimation from incompleteobservations. J Am Scat Assoc 1958;53:457-481.

  23. Mantel N. Evaluation of survival data and two new rank orden statistics arising in this consideration. Cancer Chemother Resp 1966;50:163-170.

  24. Cox DR. Regression models and life tables. J R Statist Soc 1972;74(B):197-220.

  25. Cox DR, Snell EJ. A general definition of residuals. J R Statist Soc 1968;30(A):248-275.

  26. Schoenfeld D. Chi-squared goodness of fit test for the proportional hazards regression model. Biometrika 1980;67:145-153.

  27. Schoenfeld D. Patial residuals for the proportional hazards regreession model. Biometrika 1982;69:239-241.

  28. Garfinkel L, Boring CC, Heath CW Jr. Changing trends. An overview of breast cancer incidence and mortality. Cancer 1994;74(1 suppl):222-227.

  29. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000;342(8):564-571.

  30. McMasters KM, Giuliano AE, Ross MI, Reintgen DS, Hunt KK, Byrd DR, et al. Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. N Engl J Med 1998;339(14):990-995.

  31. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986;58(12):2662-2670.

  32. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001;91(8 suppl):1679-1687.

  33. Weigand RA, Isenberg WM, Russo J, Brennan MJ, Rich MA. Blood vessel invasion and axillary lymph node involvement as prognostic indicators for human breast cancer. Cancer 1982;50(5):962-969.

  34. Connolly JL, Boyages J, Nixon AJ, Peiro G, Gage I, Silver B, et al. Predictors of breast recurrence after conservative surgery and radiation therapy for invasive breast cancer. Mod Pathol 1998;11(2):134-139.

  35. Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, et al. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 2003;97(4):926-933.

  36. Veronesi U. How important is the assessment of resection margins in conservative surgery for breast cancer? Cancer 1994;74(6):1660-1661.

  37. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003;97(1):134-147.

  38. Jmor S, Al-Sayer H, Heys SD, Payne S, Miller I, Ah-See A, et al. Breast cancer in women aged 35 and under: prognosis and survival. J R Coll Surg Edinb 2002;47(5):693-699.

  39. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71(8): 2507-2514.

  40. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68(10):2142-2149.

  41. Abner AL, Collins L, Peiro G, Recht A, Come S, Shulman LN, et al. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma. Cancer 1998;83(12): 2502-2508.

  42. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315(9):559-563.

  43. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.




2020     |     www.medigraphic.com